Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAC-MCC: FH-MCVA2TCR T-cells + Avelumab/Pembrolizumab in MCC
NCT03747484Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jul 2019
- Primary completion
- Jan 2024
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of FH-MCVA2TCR in Merkel cell carcinoma (MCC), sponsored by Fred Hutchinson Cancer Center. Started Jul 2019; status: terminated.
02
Drugs
FH-MCVA2TCR
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT03747484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03747484.